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A B S T R A C T
Converging evidence points at hypothalamus-pituitary-adrenal (HPA) axis hyperactivity and neuroinﬂammation
as important factors involved in the etiopathogenesis of major depressive disorder (MDD) and in therapeutic
eﬃcacy of antidepressants. In this study, we examined the molecular eﬀects associated with a response to a
week-long treatment with escitalopram in the chronic escape deﬁcit (CED) model, a validated model of de-
pression based on the induction of an escape deﬁcit after exposure of rats to an unavoidable stress. We conﬁrmed
our previous result that a treatment with escitalopram (10 mg/kg) was eﬀective after 7 days in reverting the
stress-induced escape deﬁcit in approximately 50% of the animals, separating responders from non-responders.
Expression of markers of HPA axis functionality as well as several inﬂammatory mediators were evaluated in the
hypothalamus, a key structure integrating signals from the neuro, immune, endocrine systems. In the hy-
pothalamus of responder animals we observed a decrease in the expression of CRH and its receptors and an
increase in GR protein in total and nuclear extracts; this eﬀect was accompanied by a signiﬁcant decrease in
circulating corticosterone in the same cohort. Hypothalamic IL-1β and TNFα expression were increased in
stressed animals, while CXCL2, IL-6, and ADAM17 mRNA levels were decreased in escitalopram treated rats
regardless of the treatment response. These data suggest that eﬃcacy of a one week treatment with escitalopram
may be partially mediated by a decrease HPA axis activity, while in the hypothalamus the drug-induced eﬀects
on the expression of immune modulators did not correlate with the behavioural outcome.
1. Introduction
Understanding the neurobiological basis of major depressive dis-
order (MDD) and the mechanisms behind the eﬃcacy of antidepressant
strategies is a pressing need for the scientiﬁc community worldwide.
One of the most reliable reported neurobiological alterations in
MDD is impaired hypothalamus-pituitary-adrenal (HPA) axis function-
ality: HPA axis hyperactivity, glucocorticoid (GC) insensitivity and CRH
overexpression in the hypothalamus or the cerebrospinal ﬂuid have
been reported in depressed patients (Sanders and Nemeroﬀ, 2016), and
similar eﬀects were observed in preclinical studies in animal models of
depression (Wang et al., 2008). Chronically elevated glucocorticoids
may exert detrimental eﬀects on the central nervous system (CNS)
functionality, cause atrophy and disruption of connectivity, especially
in the hippocampus and prefrontal cortex, and can also increase the
number of inﬂammatory cells and the production of pro-inﬂammatory
cytokines both centrally and in the periphery (Himmerich et al., 2013).
Elevated levels of inﬂammatory markers have been reported in per-
ipheral blood and spinal ﬂuid of depressed patients (Köhler et al.,
2017), while a variety of pro- and anti-inﬂammatory cytokines were
altered in the frontal cortex of subjects with MDD (Shelton et al., 2011).
HPA axis hyperactivity may be associated as well with neuroin-
ﬂammatory process: cytokines, in fact, can activate the HPA axis and
can impair glucocorticoid receptor (GR) functioning at multiple levels
(Zunszain et al., 2011): by inhibiting GR translocation to the nucleus,
GR-mediated gene transcription or by stimulating GRβ, an inactive
form of GR (Anacker et al., 2011).
Accumulating evidence, clinical and preclinical, has been reported
that the eﬃcacy of antidepressant treatments may rely on normal-
ization of hypothalamic function, by restoring GR mediated feedback
inhibition of HPA axis activity (Anacker et al., 2011; Funato et al.,
2006), and of cytokine production and plasma levels (Kenis and Maes,
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However, the eﬃcacy of currently available antidepressants is still
limited by a signiﬁcant delay between start of treatment and onset of
beneﬁcial eﬀects and by high rates of treatment resistance (Willner and
Belzung, 2015). Chronic behavioural models possess a great potential to
help elucidate and overcome these important limitations of anti-
depressant treatment because on one side they more closely mimic the
delayed pharmacological response observed in patients (O’Leary and
Cryan, 2013), and in some of them, like the chronic unpredictable stress
and chronic social defeat, is possible to separate rodents into bimodal
subpopulations that respond or not to traditional antidepressant treat-
ments (Willner and Belzung, 2015).
Along with these paradigms, also the chronic escape model of de-
pression (CED), a valid and straightforward model, that is based on the
induction of an escape deﬁcit after exposure of rats to unavoidable
stress (Benatti et al., 2012; Gambarana et al., 2001), can be used to
study pharmacological antidepressant responsiveness. In fact, we pre-
viously demonstrated that: 1. Combination of acetylsalicylic acid with
ﬂuoxetine (FLX) accelerates and potentiates the eﬀect of the anti-
depressant alone (Brunello et al., 2006); 2. After 7 days of treatment,
escitalopram (ESC) (10 mg/kg) is already eﬀective in restoring the
natural tendency to avoid a noxious stimulus in about 50% of stressed
rats developing an escape deﬁcit (Benatti et al., 2014); 3. Co-adminis-
tration of aspirin with ESC increases the treatment response rate to
escitalopram at about 75% (Brunello et al., 2007).
To investigate the molecular mechanism behind the therapeutic
eﬃcacy of antidepressants, we examined the diﬀerent molecular eﬀects
associated with a response to a week-long treatment with escitalopram
in the CED model of depression on two key elements known to be al-
tered in MDD: HPA axis functionality and cytokine production within
the CNS. We focused on the hypothalamus, the neuro-endocrine inter-
face in the brain and a key station for central circuits to orchestrate the
maintenance of body homeostasis or allostasis, that is highly responsive
to immune signals as well (MDAlboni et al., 2017a,b).
For this purpose, animals developing an escape deﬁcit were treated
for a week with escitalopram, tested for their ability to avoid a noxious
stimulus and divided in responder and non-responder as previously
reported (Benatti et al., 2014). Then, we evaluated the eﬀects of esci-
talopram on expression of CRH, its receptors (CRHR1 and CRHR2), and
heat shock protein 70 (HSP70), and also on glucocorticoid receptor
(GR) mRNA and protein levels in the hypothalamus and on circulating
corticosterone. We also measured in our model changes in hypotha-
lamic expression of pro-inﬂammatory cytokines: Interleukin (IL-) 1β,
Tumour Necrosis Factor (TNF) α, Interferon (IFN) γ, IL-6 (and its system
[IL-6R and gp130, SOCS3, ADAM10 and ADAM17]), IL-18, rat homo-




Experiments were performed on male Sprague-Dawley albino rats
(Charles River Laboratories, Calco, Italy), weighing 150–175 g at their
arrival. Animals were housed in polycarbonate cages
(38 × 15 × 22 cm; 2 per cage) with ad libitum access to food and tap
water throughout the study, and maintained under a 12 h inverted
light-dark cycle (lights on at 6.00 p.m.) at the ambient temperature of
21 + 3 °C and relative controlled humidity. Animals were left un-
disturbed for 3 weeks before beginning any behavioural procedure.
Experiments were carried out under a red light. Animals were handled
and weighed daily, from the day before the beginning of the beha-
vioural procedure throughout the whole experiment. The procedures
used in this study were in strict accordance with European legislation
on the use and care of laboratory animals (EU directive 2010/63/EU),
with the guidelines of the National Institutes of Health on the use and
care of laboratory animals (NIH Publications No.8023), and had the
approval of the Ministry of Health and of the local Ethical Committee.
All eﬀorts were made to minimize animal suﬀering and to reduce the
number of animals used in this study.
2.2. Behavioural procedures and pharmacological treatments
Animals were exposed to an unavoidable stress (US) session for the
induction of an escape deﬁcit. The US session consists of 50 min of
immobilization in ﬂexible wire nets and exposure to 80 electric shocks
(1,5 mA x 7 s, one every 30 s), through an electrode applied to the distal
third of the tail and connected to an S48 Grass stimulator as already
described (Benatti et al., 2012).
Twenty-four hours later (Day 1), rats exposed to the US and a group
of animals not exposed to the US (Naive), were tested for their re-
activity towards an avoidable noxious shock in an escape-test appa-
ratus, divided by a sliding door into two chambers one of which was
connected to an electrode applied to the tail of the rat through a sti-
mulator. All tested animals were allowed to explore the apparatus for at
least 20 min/day in the 3 days preceding the test (Fig. 1A). The test
Fig 1. Flowchart of the experimental procedure (A). Induction of the acute escape deﬁcit (B): the unavoidable stress exposed group (n = 85) underwent exposure to an acute
unavoidable stress procedure and was tested for escape deﬁcit 24 h later together with the naive group (n = 15) that was not exposed to the unavoidable stress procedure; scores are
expressed as the mean number of escapes ± S.E.M. in a test session consisting of 30 consecutive electric shocks, every 30 s. Comparisons were made by one way analysis of variance
(ANOVA), *** p < 0.0001 vs naive group (See materials and methods for a detailed description of the behavioural procedure).
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session consists of 30 consecutive electric shocks (1.2 mA× 3.5 s),
every 30 s, starting after a 5 min habituation period. Behaviour was
labelled "escape" when an animal moved to the neutral chamber of the
apparatus within this 3.5 s period (Brunello et al., 2006; Gambarana
et al., 2001).
Naive rats scored between 20 and 30 escapes out of 30 trials [mean
of the naive group at day 1 ± S.E.M. = 25.8 ± 0.60; n = 15].
Approximately 75% of rats exposed to the unavoidable stress developed
an escape deﬁcit and showed a signiﬁcantly lower mean of escapes with
respect to the naive group [6.24 ± 0.94; n = 85; ANOVA univariate; F
(1.98) = 73.51725; p < 0.0001; Fig. 1B]. After the test, animals
scoring 0–9 escapes were randomly divided in two groups and received
for 1 week an i.p. injection of either saline (1 mL/kg) (n = 14; stress) or
escitalopram (10 mg/kg/day, kindly provided by H. Lundbeck A/S.
Copenhagen-Valby, Denmark) (n = 25; escitalopram). The escape def-
icit was maintained by repeated exposure to mild unavoidable stress on
alternate days as previously described (Brunello et al., 2006;
Gambarana et al., 2001). Saline and escitalopram treated animals were
tested at day 8 with a group of naive rats (n = 15; naive) that did not
receive any treatment and were handled on alternate days (Fig. 1A). All
stress procedures and the escape tests were conducted during the dark
phase (9.00 a.m and 3 p.m.), while the pharmacological treatments
were performed before the beginning of the light phase (5:30 p.m.).
Rats were sacriﬁced by decapitation 18 h after the last injection on
day 9; hypothalamus was dissected as previously described (Alboni
et al., 2013), immediately frozen on dry ice and stored at −80 °C for
further molecular analysis.
2.3. Corticosterone serum levels
Blood samples were collected from the rat trunk after decapitation.
To improve serum separation from whole blood, samples were allowed
to clot at room temperature 15 min and 1 h on ice before centrifugation
(1000g for 15 min). Serum was transferred into clean tubes and stored
at−80 °C until the assay. All sacriﬁces were carried out between 12.00
and 15.00 p.m. (lights oﬀ). Assessment of serum corticosterone levels
was done by means of enzyme immunoassay (EIA) using a commer-
cially available kit (Arbor Assays, Ann Arbor, MI, USA), which utilizes
microplate reader set at 450 nm following the manufacturer’s instruc-
tions. Serum samples were diluted 1 : 150 in appropriate assay buﬀer
and assayed in duplicate. The detection limit of the assay was 16.9 pg/
mL; intra- and inter-assay coeﬃcients of variations were, respectively,
10.45 and 11.50%.
2.4. Total RNA extraction, reverse transcription, and real time polymerase
chain reaction
RNA extraction and DNAse treatment were performed as previously
described (Alboni et al., 2013) using GenElute™ Mammalian Total RNA
Miniprep Kit and DNASE70-On-Column DNase I Digestion Set (Sigma
Aldrich ®, Milan, Italy). Two μg of total RNA were reverse transcribed
with High Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientiﬁc, Waltham, MA USA) and Real Time PCR was performed, as
previously described, in ABI PRISM 7900 HT (Thermo Fisher Scientiﬁc,
Waltham, MA USA) using Power SYBR Green mix (Thermo Fisher Sci-
entiﬁc, Waltham, MA USA) and speciﬁc forward and reverse primers at
a ﬁnal concentration of 150 nM (see Supplementary Table 1). Ct (cycle
threshold) value was determined by the SDS software 2.2.2 (Thermo
Fisher Scientiﬁc, Waltham, MA USA), mRNA expression was calculated
with the ΔΔCt method with glyceraldehydes-3-phosphate dehy-
drogenase (GAPDH) as endogenous control.
2.5. Protein extraction
For protein extraction, hypothalami were homogenized by potter
(12 strokes at 600 rpm) in lysis buﬀer containing Hepes 10 mM, EGTA
0.1 mM, Sucrose 0.28 M, 1X Complete protease Inhibitor Cocktail
(Roche, Mannheim, Germany), Na4P2O7 5 mM, NaF 20 mM, Na3VO4
1 mM. After homogenization a fraction of the lysate was collected (total
extract) and cytosolic fraction and nuclear enriched extract were ob-
tained as previously described (Alboni et al., 2014). Protein con-
centration of the extracts was determined using standard protocol
Coomassie® reagent (Thermo Fisher Scientiﬁc, Waltham, MA USA).
2.6. Western blotting
Western blots were carried out on total extracts (40 μg) for IL-6
detection, GR protein analysis was performed on (16 μg) total, cytosolic
and nuclear enriched extracts. Electrophoresis was performed as pre-
viously described (Alboni et al., 2014). Membranes were incubated
with primary antibodies: anti-GR dil 1:1000 (anti-GR rabbit polyclonal
antibody, Santa Cruz M-20, sc-1004), anti-IL-6 dil. 1:1500 (anti-IL-6
rabbit polyclonal antibody, Abcam®, #ab6672) and anti-β-tubulin dil.
1:5000 (β-tubulin mouse monoclonal antibody, Santa Cruz D-10, sc-
5274) and then with Anti-rabbit IgG-HRP-linked Cell Signalling®,
#7071 (dil. 1:7500) as previously described (Alboni et al., 2014). Bands
were detected using Immobilon Western Chemiluminescent HRP
(Merck Millipore). The levels of protein were calculated by measuring
the peak densitometric area of the autoradiography analysed with an
image analyser (GS-690 BIORAD). Each experiment was performed
twice and the mean of the OD ratios (target/internal standard) was
analysed.
2.7. Statistical analysis
Behavioural data were expressed as the mean number of
escapes ± S.E.M. (Standard Error of the Mean) in a test session con-
sisting of 30 consecutive electric shocks, every 30 s.
For gene expression analysis, the mRNA levels of each target were
normalized to the endogenous control, GAPDH. Endogenous control
mRNA levels were not aﬀected by any treatment (p > 0.05, One-way
ANOVA). For quantitative evaluation of changes the comparative ΔΔCt
method was performed, using as calibrator the average levels of ex-
pression of naive animals.
For protein analysis, the optical densities (OD) of IL-6 and GR sig-
nals were normalized according to the OD of β-tubulin. Ratios were
expressed as percentage of naive± S.E.M.
Statistical analyses were performed using an analysis of variance
(ANOVA). Signiﬁcant changes were determined by Tukey post-hoc test
(with p< 0.05 signiﬁcance level). Eﬀect sizes for signiﬁcant results
were calculated by Cohen’s f; Cohen’s f= 0.10 was considered as small
eﬀect size, Cohen’s f= 0.25 was considered as medium eﬀect size,
Cohen’s f= 0.40 was considered as large eﬀect size (Lakens, 2013;
Thompson, 2007). Analyses were conducted using SPSS for Windows®
v.23 (SPSS Inc., Chicago, USA).
3. Results
3.1. Seven days of treatment with escitalopram (10 mg/kg) reverted the
stress-sustained escape deﬁcit condition in about 50% of the animals
To evaluate the eﬀect of a 7-day exposure to escitalopram (10 mg/
kg/mL) on the escape deﬁcit, animals were tested after one week of
treatment, with naive animals [mean of the naive
group ± S.E.M.= 23.73 ± 1.16; n = 15]. One-way ANOVA showed
a signiﬁcant diﬀerence among the groups [ANOVA univariate; F (3.53)
= 98.708, p < 0.0001, f= 1.652; Fig. 2].
As already reported for this model, about the 50% of escitalopram
treated-animals (n = 25) were responsive to the treatment and were
divided according to their performance in the escaper test into re-
sponders (n = 13) and non-responders (n = 12) (Benatti et al., 2014).
In particular the mean of escapes of escitalopram non-responder
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animals [3.33 ± 1.02; n = 12] was signiﬁcantly lower than that of the
naive group (p < 0.0001), but was not diﬀerent from saline exposed
stressed counterparts (p > 0.05). On the other hand, the number of
escapes of responders to escitalopram [22.00 ± 1.28; n = 13] was not
diﬀerent from naive animals (p > 0.05) while being signiﬁcantly
higher than the score of the stress group (p < 0.0001) (Fig. 2).
3.2. Expression of hypothalamic CRH, CRHRs and serum corticosterone
were decreased in escitalopram-receiving rats that responded to the
treatment in the CED model of depression
CRH within the brain binds mainly to two receptors CRHR1 and
CRHR2 (Sanders and Nemeroﬀ, 2016). One-way ANOVA revealed a
main eﬀect on expression levels of CRH [F (3;23) = 5.639, p = 0.006,
f= 0.516] (Fig. 3A) and its receptors CRHR1 [F (3;24) = 5.271,
p = 0.007, f= 0.476] and CRHR2 [F (3;23) = 4.786, p = 0.011,
f= 0.460] (Fig. 3A). In particular, post-hoc analysis showed a sig-
niﬁcant decrease in hypothalamic mRNA levels of CRH and its receptors
only in animals that responded to a 7 day treatment with escitalopram
with respect to naive animals (p < 0.05) (Fig. 3A).
Expression levels of GR mRNA in the hypothalamus were not altered
in our experimental conditions [F (3;24) = 1.184, p = 0.340]
(Fig. 3A). GR protein levels in animals that responded to a 7 day
treatment with escitalopram were increased in total hypothalamic ex-
tracts with respect to all the other groups [F (3;25) = 6.220, p = 0.003,
f= 0.473]. We observed an increase of GR levels in the nuclear fraction
[F (3;25) = 4.864, p = 0.009, f= 0.421] with respect to naive and
saline-receiving stressed animals (Fig. 3B). On the other hand, not re-
sponding animals receiving ESC presented an increase in GR protein
levels solely in the cytosol, with respect to the naive group and their
counterpart that responded to the treatment [F (3;25) = 4.329,
p = 0.014, f= 0.364] (Fig. 3B).
Serum corticosterone levels showed a clear decrease in stressed
animals responders to escitalopram with respect to naive animals, while
in non-responder animals no statistically signiﬁcant eﬀect was observed
[F (3;36) = 3.434, p = 0.028, f= 0.245] (Fig. 3C).
We also evaluated HSP70 expression, this protein is required for GR
heterocomplex assembly and maturation of the receptor’s hormone
binding ability (Yu et al., 2010). We found that HSP70 mRNA levels
were signiﬁcantly increased in animals that after 7 days of treatment
with escitalopram were considered non-responder [F (3;24) = 4.960,
p = 0.009, f= 0.456] with respect to their responder counterparts,
stressed animals receiving saline, and naive animals (Fig. 3A).
3.3. mRNA levels of IL-1β and TNF-α were increased in the hypothalamus
of stressed rats in the CED model of depression
Increased pro-inﬂammatory cytokines have been reported in several
stress-based rodent models of depression (Kenis and Maes, 2002; You
et al., 2011). One-way ANOVA revealed a main eﬀect for IL-1β and
TNF-α expression [F (3;23) = 3.506, p = 0.034, f= 0.367 and F
(3;23) = 3.814, p = 0.027, f= 0.406 respectively] (Fig. 4A), post-hoc
revealed a signiﬁcant increase in hypothalamic mRNA levels of both
pro-inﬂammatory cytokines in stressed animals treated for 7 days with
saline with respect to the naive group, while stressed animals receiving
escitalopram for 7 days were not diﬀerent from naive animals. One-way
ANOVA failed to reveal a main eﬀect in our experimental condition on
expression levels of IFN-γ and IL-18 in the rat hypothalamus [F (3;23)
= 1.256; p = 0.316 and F (3;24) = 0.893; p = 0.461 respectively]
(Fig. 4A).
CXCL1 (also known as keratinocyte-derived chemokine, KC) and
CXCL2 (macrophage inﬂammatory protein, MIP-2), in rodents perform
the same functions as human CXCL8 (also known as IL-8) (Alboni et al.,
2013). CXCL1 mRNA levels were not aﬀected in our experimental
conditions [F (3;24) = 1.742; p = 0.189], while CXCL2 expression was
decreased in rats exposed to escitalopram irrespective of the beha-
vioural outcome [F (3;22) = 4.484; p = 0.015, f= 0.456] (Fig. 4B).
No eﬀect was observed in our experimental condition on the hy-
pothalamic expression levels of the anti-inﬂammatory cytokines IL-4
and IL-10 [F (3;24) = 1.802; p = 0.178 and F (3;22) = 0.490;
p = 0.693 respectively] (Fig. 4C).
3.4. Hypothalamic IL-6 and ADAM17 mRNAs were decreased by a 7-day
treatment with escitalopram in the CED model of depression
IL-6 appears to be one of the most reliable markers of inﬂammation
associated with mood and anxiety disorders (Köhler et al., 2017). IL-6
mRNA was signiﬁcantly decreased in the hypothalamus of rats exposed
to the unavoidable stress and treated for 7 days with escitalopram ir-
respective of the treatment outcome: both responder and non-responder
to the drug showed lower levels of expression of this pleiotropic cyto-
kine [F (3;23) = 3.884, p = 0.024, f= 0.396] (Fig. 5A). Protein levels
of IL-6 did not diﬀer between naive animals and stressed animals re-
ceiving saline or escitalopram [F (3.25) = 1.295; p = 0.298] (Fig. 5C).
We also investigated the main eﬀect on the hypothalamic expression
levels of several other members of IL-6 system in our experimental
conditions. No eﬀect on expression levels of both subunits of IL-6 re-
ceptor: IL-6 receptor (IL-6R), gp130 (signal-transducing receptor) and
IL-6 responsive suppressor of cytokine 3 (SOCS3) were observed in the
rat hypothalamus in our experimental conditions. Neither exposure to
stress nor a 7-day treatment with the antidepressant aﬀected mRNA
levels of these targets [F (3;21) = 1.332; p = 0.295 for IL-6R, F (3;21)
= 1.084; p = 0.377 for gp130, F (3;22) = 0.394; p = 0.759 for
SOCS3] (Fig. 5A).
The classic IL-6 signalling is mediated by the complex IL-6/IL-6R/
gp130, while IL-6 trans-signalling is mediated by a soluble form of IL-
6R (sIL-6R), generated either by alternative splicing or by proteolytic
cleavage mediated mainly by two speciﬁc members of the ADAM (a
disintegrin and metalloproteinase) family, ADAM17 and ADAM10
(Rose-John, 2012). Considering that neurons and astrocytes express
high levels of gp130 and low levels of IL6R, sIL-6R may be crucial for
IL-6-mediated neuroinﬂammatory eﬀects on these cells (Maes et al.,
Fig. 2. A 7-day treatment with escitalopram reverted the stress-induced escape
deﬁcit in approximately 50% of the animals. The escitalopram non-responder
(n = 12) group scored less than 9 escapes, while escitalopram-responder rats performed
more than 15 escapes (n = 13) in the escape test. Animals were treated for 7 days with
either saline (1 mL/kg) (Stress; n = 14) or escitalopram 10 mg/kg (ESC; n = 25), ex-
posed to mild unavoidable stress on alternate days, and then tested for escape ability with
the naive group (n = 15). Scores are expressed as the mean number of escapes ± S.E.M.
out of 30 consecutive electric shocks. Comparisons were made by one way analysis of
variance (ANOVA), followed by Tukey post-hoc test ***p < 0.0001 vs naive group;
°°°p < 0.0001 vs stress group.
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2014). The trans-signalling pathway is considered pro-inﬂammatory
and is implicated in several chronic inﬂammatory diseases (Burton
et al., 2011).
While no main eﬀect was revealed for ADAM10 [F (3;22) = 0.321,
p = 0.810], ADAM17 mRNA levels were signiﬁcantly decreased in rats
treated with escitalopram for 7 days irrespective of the outcome at the
escape test with respect to both naive untreated animals and the stress
group receiving saline [F (3;23) = 8.306, p = 0.001, f= 0.667]
(Fig. 5B).
4. Discussion
In this study we employed the chronic escape deﬁcit model of de-
pression, an animal model in which a stress-induced behavioural
change can be restored by an antidepressant treatment (Brunello et al.,
2006; Gambarana et al., 2001; Raone et al., 2007). This model allowed
us to study the diﬀerent eﬀects of a therapeutic treatment in anti-
depressant responders and non-responders, in fact here we conﬁrmed
that a 7-day treatment with escitalopram restored the natural tendency
to avoid a noxious stimulus in about 50% of stressed rats, in agreement
with our previous results (Benatti et al., 2014) and results obtained with
other behavioural paradigms (Jayatissa et al., 2006). At the molecular
level, ﬁrst we demonstrated that the treatment outcome was associated
with decreased expression of CRH, CRHRs and increased GR translo-
cation in the hypothalamus, and decreased circulating corticosterone.
Secondly, we conﬁrmed that escitalopram exerted an inhibiting eﬀect
on IL-6 and CXCL2 hypothalamic transcription, in both responders and
non-responders.
Converging evidence points at HPA axis hyperactivity and neu-
roinﬂammation as important factors involved in the etiopathogenesis of
major depressive disorder (MDD) and in therapeutic eﬃcacy of anti-
depressant drugs (Benatti et al., 2016).
In the CED model of depression, animals responding to a week-long
escitalopram treatment showed a signiﬁcant decrease in circulating
levels of corticosterone with respect to naive animals, while serum le-
vels of corticosterone of the group not responding to escitalopram were
not diﬀerent from unstressed rats. Other groups demonstrated that a 4
week exposure to escitalopram was able to decrease circulating corti-
costerone levels in control animals (Doron et al., 2014; Flandreau et al.,
2013), in our condition this eﬀect was present only when the drug re-
stored in the animals the ability to avoid noxious stimuli. No diﬀerence
was observed in serum corticosterone levels between naive and animals
stressed for a week, while an increase in plasma corticosterone levels
was induced in this model after a 4-week unavoidable stress procedure
(Raone et al., 2007). In these conditions Raone and co-workers reported
also higher CRH levels and decreased GR in the hypothalamus of
stressed animals (Raone et al., 2007). Acute and chronic stress have
been shown to cause an increase in CRH hypothalamic expression (de
Andrade et al., 2014) and increased CRH concentrations were reported
in the cerebrospinal ﬂuids of depressed subjects. Chronic AD treatment
was able to attenuate both the stress-induced increase in CRH expres-
sion in the PVN of rats (Stout et al., 2002) and also in patients with
MDD (Veith et al., 1993). CRH actions are mediated by its receptors
CRHR1 and CRHR2: CRHR1 is able to recruit anxiety-like behaviour,
blocking CRHR1 can reverse or inhibit the stress-induced behavioural
alterations in several animal models of depression (Jutkiewicz et al.,
2005). However the role of CRHR2 in stress response and depressive-
like behaviour remains unclear and may vary according to brain region
or the preclinical model (Sanders and Nemeroﬀ, 2016).
Here we reported that hypothalamic expression of CRH and both its
receptors were decreased in animals that responded to a week-long
treatment with escitalopram. Consistently with our result, it has been
proposed that downregulation of CRH activity may be a common
pathway of antidepressant therapeutic eﬀect (Licinio et al., 2004). In
control, unstressed, animals we failed to observe a reduction in hy-
pothalamic CRH expression following a chronic treatment with
Fig. 3. Hypothalamic CRH and CRHRs mRNA levels and serum corticosterone were decreased in escitalopram-receiving rats that responded to the treatment. Animals were
treated for 7 days with either saline (1 mL/kg) (Stress; n = 7-10) or escitalopram (ESC) 10 mg/kg, exposed to mild unavoidable stress on alternate days, and then tested for escape ability
with the naive group (n = 7-10). Escitalopram-receiving rats were divided in responder (n = 5-10) and non-responder (n = 4-10) according to their performance. CRH, CRHR1, CRHR2,
Heat Shock protein 70 (HSP70), GR hypothalamic mRNA expression (A), with GAPDH as endogenous control, were measured by Real-time PCR. Hypothalamic GR protein levels (B) were
determined by western blotting in total extracts, cytosolic and nuclear fractions. Serum corticosterone (CORT) was measured by EIA (C). Data are represented as means ± S.E.M. and
were analysed with ANOVA followed by Tukey (*p < 0.05 is signiﬁcant diﬀerence with respect to naive group; °p < 0.05 is signiﬁcant diﬀerence with respect to stress group;
•p < 0.05 is signiﬁcant diﬀerence with respect to ESC-responder).
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diﬀerent classes of antidepressants (unpublished observation), sug-
gesting that only the combination of the stressful procedure with esci-
talopram exposure is able to aﬀect CRH gene expression. The molecular
mechanism underlying the reduced transcription of CRH and its re-
ceptor in the hypothalamus of animals responding to escitalopram may
be mediated by an increase in GR feedback sensitivity or by altering
transcription of GR-responsive genes. After 7 days of treatment GR
protein, but not mRNA, levels were signiﬁcantly increased in the hy-
pothalamus of escitalopram responders, in particular in total extracts
and in the nuclear-enriched fraction, this eﬀect was not present in non-
responder animals, where a 7-day exposure to escitalopram induced an
accumulation of glucocorticoid receptors in the cytosol. GRs once
translocated in the nucleus exert a negative regulation on transcription
of several genes, CRH itself, mostly in the hypothalamus (Yamamori
et al., 2007). A GR-mediated decrease of CRH transcription coupled
with a decrease in CRH protein levels could result in a decreased acti-
vation of the HPA axis, this chain of events could underlie the decrease
of corticosterone serum levels in escitalopram treated rats that re-
sponded to the treatment.
We observed also an upregulation in HSP70 hypothalamic tran-
scription speciﬁcally in non-responder animals. HSP70 controls the
activation of glucocorticoid receptor, and its expression appears to be
regulated by several stimuli, including stress (Pae et al., 2007); future
studies will be needed to further understand the biological con-
sequences of an increase in HSP70 mRNA levels in animals not re-
sponding to escitalopram, especially because this family of proteins is
proposed to play a role in the response and eﬃcacy of antidepressant
treatments (Wang et al., 2008).
Major depression may be associated with immune activation, and
chronic stress-induced GC resistance may dampen anti-inﬂammatory
processes and induce prolonged production of pro-inﬂammatory med-
iators (Joana et al., 2016). In fact, numerous acute and chronic stress
paradigms are able to induce the expression of pro-inﬂammatory
markers, including TNF-α, IL-1β, and IL-6. Here, we demonstrated a
general increase in IL-1β and TNFα expression in the hypothalamus of
stressed animals in which the natural tendency to avoid a noxious sti-
mulus is disrupted, this eﬀect was not observed in their counterparts
that received a 7-day treatment with escitalopram, irrespective of the
outcome. Expression levels of other pro-, such as IL-18 or IFN-γ, or anti-
inﬂammatory, IL-4 and IL-10, cytokines were not altered in this beha-
vioural paradigm. These data conﬁrm the idea that an increase in the
expression of pro-inﬂammatory mediators is not a universal response to
all stressors (Blandino et al., 2009), in fact a stimulatory threshold for
each cytokine to be increased within the CNS, and a speciﬁc time frame
Fig. 4. Eﬀect of a 7 day treatment with escitalopram on hypothalamic expression of the main pro- and anti-inﬂammatory cytokines in the CED model of depression. Animals
were treated for 7 days with either saline (1 mL/kg) (Stress; n = 7) or escitalopram (ESC) 10 mg/kg, exposed to mild unavoidable stress on alternate days, and then tested for escape
ability with the naive group (n = 7). Escitalopram-receiving rats were divided in responder (n = 5) and non-responder (n = 5) according to their performance in the test. Interleukin (IL-
) 1β, Tumour Necrosis Factor (TNF) α, Interferon (IFN) γ, and IL-18 (A), CXCL1 and CXCL2 (B), IL-4 (H) and IL-10 (C), hypothalamic mRNA expression, with GAPDH as endogenous
control, were measured by Real-time PCR. Data are represented as means ± S.E.M. and were analysed with ANOVA followed by Tukey (*p < 0.05 is signiﬁcant diﬀerence with respect
to naive group).
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for detecting these changes may be necessary (Deak et al., 2005).
The unavoidable stress that induces the behavioural alteration in
the CED model is a combination of restraint and electric shocks, in-
creased hypothalamic IL-1 has been observed after exposure to im-
mobilization (Suzuki et al., 1997), and footshock (Blandino et al.,
2009). Data on TNF-α and stress are less consistent: studies reported an
hyperproduction of TNF-α induced by acute and chronic stress para-
digms or in animal models of depression (Himmerich et al., 2013), as
well as a decrease in its expression in diverse stress situations (Joana
et al., 2016). Also IL-6 can be considered a stress-responsive cytokine
(Jankord et al., 2010), but we failed to observe any diﬀerence in hy-
pothalamic levels of mRNA or protein for this cytokine between
stressed and naive animals. The lack of protein increase is consistent
with observation from other group who reported changes in protein in
the CUS model after 14 days, but not after 7 days while they observed
an increase in mRNA levels following several chronic stressors (Girotti
et al., 2013). It is possible that the induction occurred at a diﬀerent time
point or that the translated protein was released, in fact IL-6 can act
within the hypothalamic nuclei or be secreted from neural lobe
(Jankord et al., 2010).
Hypothalamic CXCL2, one of the rodent analogues of IL-8, was
signiﬁcantly decreased in escitalopram treated rats regardless of the
treatment response. Data on the association between the chemokine IL-
8 and depression are inconsistent (Kenis and Maes, 2002; Young et al.,
2014), however we have previously demonstrated a decrease in CXCL2
hypothalamic transcription in control animals exposed to a chronic
treatment with the SSRI ﬂuoxetine, but not the tricyclic antidepressant
imipramine (Alboni et al., 2013). In depressed patients, IL-8 serum
changes were reported during escitalopram monotherapy regardless of
treatment response (Eller et al., 2009). Given that IL-8 may have both
pro and anti-inﬂammatory properties and that CXCL1 and CXCL2 may
act as neuroprotective or neurotrophic agents, its exact involvement in
antidepressant response requires further investigation.
In our experimental conditions, IL-6 expression is decreased in the
hypothalamus of CED-animals following escitalopram exposure for
7 days irrespective of the treatment outcome. Molecular eﬀects
common to responders and non-responders may be ascribed to the ex-
posure to the drug itself and may not likely participate in mediating its
therapeutic outcome. In accordance, a downregulation of hypothalamic
IL-6 mRNA was observed in control, unstressed rats after a chronic
exposure with either ﬂuoxetine or imipramine (Alboni et al., 2013). The
time taken by escitalopram or ﬂuoxetine to downregulate IL-6 (and
CXCL2) in the hypothalamus is consistent with the treatment duration
that resulted eﬀective in the CED and other behavioural models of
depression (Benatti et al., 2014; Brunello et al., 2006; Gambarana et al.,
2001; Reed et al., 2009).
Interestingly, we have previously reported that IL-6 expression was
decreased as well in the hippocampus of CED animals following a week-
long escitalopram treatment, but only in the group that responded to
the treatment with respect to naive controls (Benatti et al., 2014).
Hippocampus and hypothalamus are known to be involved in mood and
neuroendocrine regulation (Girotti et al., 2013; Han et al., 2005), with
the hippocampus extensively projecting to the hypothalamus and gov-
erning HPA axis activity (Surget et al., 2011). Given their diﬀerent roles
and functions, numerous data from the literature concur that molecular
impacts of stress and antidepressants are brain region-speciﬁc, with
diﬀerent therapeutic targets for each brain area (Alboni et al., 2010;
Alboni et al., 2017a,b; Surget et al., 2009). Area speciﬁc eﬀect on IL-6
transcription may aﬀect diﬀerent functions (Aniszewska et al., 2015),
however the decrease in IL-6 mRNA was not complemented by de-
tectable changes in IL-6 receptors and SOCS3, a STAT3 target gene or in
IL-6 protein levels (Girotti et al., 2013).
Interestingly, depression is not only associated with changes in
serum levels of IL-6 but also of the soluble IL-6R (sIL-6R) (Maes et al.,
2014). IL-6 trans-signalling pathway, mediated by sIL-6, is considered
pro-inﬂammatory and is implicated in several chronic inﬂammatory
diseases (Burton et al., 2011). We observed a down regulation in IL-6R
cleaving enzyme ADAM17, but not ADAM10, mRNA levels following
Fig. 5. A 7-day treatment with escitalopram decreased hypothalamic IL-6 and ADAM 17 expression in the CED model of depression. Animals were treated for 7 days with either
saline (1 mL/kg) (Stress; n = 6-7) or escitalopram (ESC) 10 mg/kg, exposed to mild unavoidable stress on alternate days, and then tested for escape ability with the naive group (n = 6-
7). Escitalopram-receiving rats were divided in responder (n = 5-7) and non-responder (n = 4-5) according to their performance in the test. IL-6, IL-6R, gp130, and SOCS3 (A), ADAM17
and ADAM10 (B) hypothalamic mRNA expression, with GAPDH as endogenous control, were measured by Real-time PCR. IL-6 protein levels (C) in the hypothalamus were determined by
western blotting in total extract. Data are represented as means ± S.E.M. and were analysed with ANOVA followed by Tukey (*p < 0.05 is signiﬁcant diﬀerence with respect to naive
group; °p < 0.05 is signiﬁcant diﬀerence with respect to stress group).
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escitalopram exposure. Evidence suggests a diﬀerent role for these two
enzymes: ADAM10 is known to mediate the constitutive cleavage, while
ADAM17 is responsible for the inducible cleavage (Chalaris et al.,
2010), it is possible that ADAM17 is the master regulator for the gen-
eration of the soluble IL-6R. So far, no data on the eﬀect of anti-
depressants on ADAM17 expression are available, while higher baseline
levels were demonstrated in the hippocampus of aged mice.
5. Conclusion
The CED model allowed us to evaluate the molecular eﬀects elicited
by a seven-day exposure to escitalopram in two populations that re-
sponded to or not to the treatment. Our results strengthened the as-
sumption that escitalopram mediated reversion of stress- induced im-
paired behaviour is associated with a modulation of the HPA
functionality in the hypothalamus. In fact, here we demonstrated that
an eﬀective treatment with escitalopram caused a general decrease in
circulating corticosterone, and that this peripheral eﬀect was correlated
with a modulation of CHR/CRHRs transcription and GR activity in the
hypothalamus, a key area involved in central regulation of the HPA
axis. On the other hand, escitalopram appears to modulate hypotha-
lamic transcription of inﬂammatory mediators regardless of the beha-
vioural outcome. Future studies aimed at unravelling the separate and
interacting roles of the HPA axis and immune systems in key areas of
the CNS such as hypothalamus, hippocampus or frontal cortex in the
CED model will advance our comprehension of responsiveness to
therapeutic treatment and help to identify and isolate the molecular
mechanisms most rigorously sustaining the therapeutic eﬃcacy.
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